Exploring the Readiness of Gene Therapy for Treating Optic Nerve Disease

Gene Therapy and Optic Nerve Disease

Overview of Gene Therapy

Gene therapy is emerging as a promising approach for addressing genetic defects. Recent research in the United States has examined whether gene therapy is ready to be applied to the treatment of optic nerve diseases.

Understanding Optic Nerve Disease

Optic nerve disease encompasses a range of conditions that result in the degeneration of retinal ganglion cells. These specialized neurons serve an essential role by transmitting visual information from the eyes’ photoreceptors to the brain, akin to a truck delivering packages from a warehouse to a customer’s home. Unlike other neurons in the peripheral nervous system, which have the ability to regenerate, retinal ganglion cells do not possess this capability, leading to significant pain and vision loss for affected patients.

During embryonic development, retinal ganglion cells exhibit a strong regenerative capacity, which is regulated by specific genes. However, as these cells mature, the expression of these genes is turned off, diminishing their regenerative potential. This leads scientists to explore the possibility of reactivating these genes as a potential treatment for optic nerve diseases.

Gene Therapy Mechanism

Gene therapy aims to treat genetic disorders by correcting defective DNA within patients. Typically, this involves using a bioengineered virus to deliver healthy genes into diseased tissues. The virus infects adjacent cells, providing them with a functional copy of the gene, thereby restoring normal cellular function. Although the concept of utilizing viruses may seem counterintuitive, these are specifically designed and rigorously tested to ensure their safety for genetic manipulation in patients.

Leber’s Hereditary Optic Neuropathy

Leber’s hereditary optic neuropathy (LHON) is a common optic nerve disease attributed to genetic mutations, leading to progressive retinal ganglion cell degeneration. Approximately 60-90% of LHON patients carry a prevalent mutation in the NADH dehydrogenase gene, making this condition an ideal candidate for gene therapy research due to its large sample size and straightforward genetic correction.

Studies investigating gene therapy in LHON patients have yielded promising yet varied results. In one 2016 study, nine patients received gene therapy treatments, and after nine months, seven showed significant improvement in best-corrected visual acuity, indicating enhanced visual sharpness. However, two patients who initially improved experienced a decline in vision over 36 months, suggesting that the benefits may be temporary.

In another ongoing study, researchers administered varying doses of gene therapy to LHON patients. Early findings indicate that those with at least six months of LHON symptoms did not benefit from low-dose gene therapy. In contrast, medium-dose patients and recent LHON patients receiving low doses exhibited significant improvements in visual acuity. These results suggest that the timing of gene therapy may be critical, with the best outcomes occurring early in the course of LHON.

Challenges in Retinal Ganglion Cell Regeneration

One of the key pathways involved in retinal ganglion cell regeneration is the mTOR signaling pathway. As these cells mature, genes that regulate PTEN inhibit mTOR activity, leading to a loss of regenerative capacity. Research in mice has demonstrated that inhibiting PTEN through gene therapy can enhance retinal ganglion cell regeneration following optic nerve damage. Additionally, promoting neuroglobin, a neuroprotective protein, has been shown to prevent retinal ganglion cell degeneration in glaucoma models.

Another study found that targeting anti-Klf9 through gene therapy offers protection against chemical injuries to retinal ganglion cells and promotes regeneration. However, a significant challenge in applying gene therapy to optic nerve diseases lies not only in stimulating regeneration but also in maintaining proper neural networking. The eye contains millions of interconnected neurons that must communicate effectively with the brain for clear vision. Poor networking, even with physiologically normal eyes, can result in visual anomalies such as macular hypoplasia.

Future Directions and Obstacles

Gene therapy offers substantial promise for treating genetic defects, especially in the context of optic nerve diseases. The recent review of gene therapy’s effectiveness in treating optic nerve conditions has revealed encouraging results alongside considerable challenges. Current gene therapy approaches in both humans and animal models have demonstrated significant potential for retinal ganglion cell regeneration following optic nerve injury.

Although early intervention appears to enhance the success of gene therapy for optic nerve diseases, researchers face the daunting task of improving neural networking to ensure safety and efficacy for patients suffering from these conditions.

References

(1) DeBusk, A. & Moster, M. L. Gene therapy in optic nerve disease. Curr. Opin. Ophthalmol. 1 (2018). doi:10.1097/ICU.0000000000000473
(2) Poulter, J. A. et al. Recessive mutations in SLC38a8 cause foveal hypoplasia and optic nerve misrouting without albinism. Am. J. Hum. Genet. 93, 1143–1150 (2013).